AbbVie, Lilly atopic dermatitis hopefuls hit with more delays as FDA’s JAK inhibitor holdups carry onnews2021-07-16T15:17:37+00:00July 16th, 2021|Fierce Pharma|
Alexion’s Ultomiris notches myasthenia gravis win amid quest for 3rd Soliris usenews2021-07-16T13:29:10+00:00July 16th, 2021|Fierce Pharma|
Budget proposal to allow Medicare to negotiate prices should ‘enrage’ seniors, PhRMA saysnews2021-07-16T13:13:39+00:00July 16th, 2021|Fierce Pharma|
From masking to vaccines, Ad Council corrals feds, brands and media into COVID-19 campaignsnews2021-07-16T12:55:35+00:00July 16th, 2021|Fierce Pharma|
Biogen, ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer’s drugnews2021-07-16T05:30:53+00:00July 16th, 2021|Fierce Pharma|
Pfizer antes up $345M to settle long-running EpiPen antitrust claims as Viatris case moves aheadnews2021-07-16T01:18:18+00:00July 16th, 2021|Fierce Pharma|
AstraZeneca, FibroGen hit another roxadustat setback as FDA panel calls for more safety datanews2021-07-15T20:36:12+00:00July 15th, 2021|Fierce Pharma|
Fierce Pharma Asia—Sinovac, Sinopharm to supply 500M vaccine doses to COVAX; 2 approvals for Seagen-Astellas’ Padcevnews2021-07-15T19:36:30+00:00July 15th, 2021|Fierce Pharma|
Takeda, AbbVie, BMS, Sanofi, Lilly and others join growing tally of pharma’s July price hikes: reportnews2021-07-15T15:25:55+00:00July 15th, 2021|Fierce Pharma|
Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie’s launches win on value: reportnews2021-07-15T15:22:46+00:00July 15th, 2021|Fierce Pharma|
